Kornimate/medical-research-clean huggingface dataset:
the study of eustachian tube dysfunction and laryngopharyngeal reflux

Conditions: Eustachian Tube Dysfunction; Laryngopharyngeal Reflux

Summary: the purpose of this study is to investigate the relationship between ear fullness, pressure, and/or pain and laryngopharyngeal reflux, in order to focus medical therapy and improve therapeutic outcomes in this patient population.


Eligibility criteria:
inclusion criteria: * they complain of symptoms of ear fullness, ear pain, and/or ear pressure, either unilateral or bilateral * they are willing to participate in the study. * they are between the ages of 18 to 80 exclusion criteria: * they have had major ear surgery (not including tympanostomy tubes) * they have a medical condition that is another possible etiology of ear pain or acid reflux and may require additional medical or surgical intervention such as: acute or chronic otitis externa, chronic otitis media, temporomandibular joint dysfunction, upper aerodigestive track neoplasm, history of head/neck radiation therapy. * they are pregnant. proton pump inhibitors are a category c drug with unknown pregnancy risks. * they do not wish to participate in the study * they are \ 80.

Keywords: ear pressure ear fullness ear pain etd laryngopharyngeal reflux lpr gastroesophageal reflux disease gerd nasopharyngeal reflux acid reflux
the impact and benefit of physical activity on premature ejaculation

Conditions: Premature Ejaculation

Summary: the purpose of this study is to investigate the relationship between physical activity and pe, and determine whether moderate physical activity might delay ejaculation time or be an alternative treatment for pe.


Eligibility criteria:
inclusion criteria: * sexually active, heterosexual patients without regular physical activity or erectile dysfunction, and had a sexual partner for at least six months, and sexual intercourse at least twice a week exclusion criteria: * use of medications for endocrinological, metabolic, chronic systemic, or psychiatric diseases, use of alcohol or addictive substances, or use of drugs that might affect erection and ejaculation, presence of patients with peyronie's disease, chronic prostatitis, urethritis, or active urinary tract infection, and absence of regular physical activity or previous treatment for premature ejaculation.

Keywords: intravaginal ejaculatory latency time international physical activity questionnaire premature ejaculation diagnostic tool
intraoperative frozen section pathology to diagnose the iaslc grades for lung adenocarcinoma (ectop-1014)

Conditions: Lung Adenocarcinoma; Surgical Procedure, Unspecified; Pathology

Summary: this study is one of eastern cooperative thoracic oncology projects (ectop-1014). the goal of this clinical trial is to confirm the concordance rate between intra-operative frozen section pathological diagnosis and post-operative paraffin embedded pathological diagnosis, and use this result to guide surgical treatment for early stage (ct1n0m0) lung adenocarcinomas.


Eligibility criteria:
inclusion criteria: * patients who sign the informed consent form and are willing to complete the study according to the study protocol; * no previous history of cancer or pulmonary surgery; * solitary lesions or multiple lesions with only one not manifesting as pure ground-glass opacity (ggo) on ct scan; * peripheral clinical t1n0m0 patients that are eligible for surgery; * non-small cell lung cancer is pathologically diagnosed before or at surgery; * no radiation therapy or chemotherapy before surgery. exclusion criteria: * patients with clinical stages other than t1n0m0; * the lesion cannot be completely resected; * previous history of cancer; * patients having received radiation therapy or chemotherapy.

Keywords: intraoperative frozen section pathology surgical treatment lung adenocarcinoma
complementary or alternative medicine practices used by women at increased risk for breast cancer

Conditions: Breast Cancer

Summary: rationale: increasing knowledge about the complementary or alternative medicine practices used by women who are at increased risk for breast cancer may provide useful information for planning breast-cancer-prevention strategies. purpose: clinical trial to determine how many women who are at increased risk for breast cancer use complementary or alternative medicine.

objectives: i. determine the prevalence of complementary or alternative medicine (cam) practices among adult women who are enrolled in the risk assessment clinic at the national naval medical center breast care center and are found to be at increased risk for developing breast cancer. ii. correlate the use of cam with individual risk for breast cancer. iii. define the types of cam practices used by this study population. iv. identify reasons why this study population is using cam. outline: patients are stratified according to prevalence of complementary and alternative medicine practices (enteral/parenteral vs psychologic/neurologic). patients complete a personal risk assessment form, pre-test/post-test knowledge questionnaires, and a survey questionnaire. projected accrual: a total of 102 patients will be accrued for this study within approximately 2 years.

Eligibility criteria:
disease characteristics: enrolled in the risk assessment clinic (rac) of the national naval medical center and found to be at increased risk for breast cancer based on at least one of the following: estimated risk of at least 1.7% for developing breast cancer over the next 5 years, as determined by the breast cancer risk assessment tool (bcrat) prior history of lobular carcinoma in situ or ductal carcinoma in situ family history of breast or ovarian cancer consistent with autosomal dominant pattern of inheritance or empirically elevated risk of breast cancer based on a single first- or second-degree relative with breast or ovarian cancer must have attended the rac education session within past 3-6 months hormone receptor status: not specified patient characteristics: age: 18 and over sex: female menopausal status: not specified performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no other prior cancer except ductal carcinoma in situ or basal cell carcinoma able to read and understand english prior concurrent therapy: not specified

Keywords: breast cancer
embryo health study

Conditions: Infertility; Hereditary Diseases

Summary: this study intends to determine the patients' perception and motivation to obtain additional information on their preimplantation embryos' risks of polygenic disorders. patients undergoing ivf and genetic testing on their embryos for aneuploidies will be given the option to obtain information of their embryos' polygenic disease risk after receiving genetic counseling.

patients planning to use pgt-a and who meet the inclusion criteria will be offered participation by their ivf physician prior to initiating cycle stimulation. eligible and interested patients will be contacted, counseled and consented for participation in the study by a genetic counselor at genomic prediction clinical laboratory. this will include genetic counseling to address the benefits and limitations of pgt-a and pgt-p, the family history of diseases currently tested under pgt-p, what diseases they may be interested in testing, the process of obtaining saliva samples, and the information provided by pgt-p results. a total of 500 patients will complete the study and may be recruited from any ivf clinic in the united states. after being enrolled in the study, patients will have two options. one option is to receive pgt-a results first and then decide if they wish to receive the pgt-p results. a second option is to receive a single comprehensive report. all patients will receive a report indicating the predicted karyotype of each embryo (pgt-a) and, according to which option they elected, may also receive a report on any or all of the following elected diseases: type 1 diabetes, type 2 diabetes, coronary artery disease, heart attack, hypercholesterolemia, hypertension, testicular cancer, prostate cancer, malignant melanoma, breast cancer, basal cell carcinoma. furthermore, a genetic ancestry test will be performed on each submitted saliva sample to determine potential pgt-p performance and which disease predictors can be computed based on the patients ethnic background.

Eligibility criteria:
inclusion criteria: * all couples of caucasian or east asian ancestry above the age of 18 who elect to have pgt-a as part of their ivf treatment cycle. exclusion criteria: * any case where biological parental dna is unavailable. * any case involving pgt-m or pgt-sr.
internet-based diabetes education and case management

Conditions: Diabetes Mellitus; Hypertension

Summary: this study is comparing the effectiveness of web-based care management to either telephone-based care management or internet access alone, in patients with poorly controlled diabetes mellitus.

background: patients with diabetes and elevated hemoglobin a1c (hba1c) are at risk for diabetes-related complications. care-management may be helpful in these patients, by providing direct contact between such high-risk patients and the healthcare system. web-based systems have previously shown promise as a means of neutralizing access barriers such as scheduling and travel to appointments and may be of particular help in improving diabetes care. objectives: we examined the efficacy of two methods of diabetes education and care management: (1) a traditional model that involved telephone contact and face-to-face encounters (2) a web-based model with access to a diabetes care management web site. we compared these interventions to a study group that received no education or care management but was provided with a computer and access to diabetes self-management websites. methods: this study employed a randomized, parallel group design involving patients with diabetes mellitus and an elevated hba1c ( 8.5%). participants assigned to web-based care management received a notebook computer, internet access and interacted with a care manager through a diabetes education and care management website. participants receiving telephone-based care management interacted with a care manager using telephone and face-to-face contact. both care management models employed medication algorithms to improve glucose and bp control. these care management groups were compared to a study group that had no care management but received a notebook computer and internet access with their "home page" containing links to a series of diabetes self-management websites (i.e. computer only group). the primary outcome measures were hba1c, blood pressure, and scores on the problem areas in diabetes (paid) questionnaire, each measured over 12-months. status: complete

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus * age 25-79 years * hba1c \>=8.5% * ability to speak and understand english * telephone access * va-based primary care provider * interest in using a glucose and bp monitor and notebook computer exclusion criteria: * visual impairment that affects ability to read

Keywords: diabetes mellitus hypertension telemedicine case management
a comparison study of apadenoson and adenosine to treadmill exercise stress.

Conditions: Coronary Artery Disease

Summary: the purpose of this clinical research study is to compare apadenoson and adenosine to treadmill exercise stress spect mpi


Eligibility criteria:
inclusion criteria: * clinically appropriate for exercise stress testing exclusion criteria: * contraindication to adenosine stress or inability to perform treadmill exercise test
preliminary study for identification of calcium-binding proteins in the serum in various metabolic bone disorders

Conditions: Osteoporosis; Osteitis Deformans; Parathyroid Diseases

Summary: the purpose of this study is to determine whether the serum levels of certain calcium-binding proteins may be helpful in the diagnosis and management of metabolic bone diseases.

osteoporosis is an important and costly health issue. the diagnosis of the disease is based on measurement of bone mineral density or the occurrence of characteristic fractures. currently it is not possible to predict fractures in individual patients, and the ability to monitor the response to treatment is limited as well. we have synthesized and characterized a novel photoreactive ca2+-analog reagent, azido ruthenium (azru) that binds covalently to ca2+-binding sites in proteins. the specificity of azru for ca2+-binding proteins, its photoactivation and its radioactive labeling pave the way for a wide use of azru as a powerful tool to assess ca2+-dependent cellular processes, both in vitro and in vivo. using radiolabeled azru, it will be possible to identify ca2+-binding proteins in a biological sample such as whole cell, isolated mitochondria, er or other protein containing fractions. protein bound \[103ru\]azru in biological sample can be separated by sds gel electrophoresis, followed by coomassie staining and exposure of the dried gel to x-ray film (autoradiography). this allows the identification of the \[103ru\] radiolabeled proteins. the labeled protein bands can be cut from the gel and subjected to maladi-tof analysis and the identity of the protein can be determined by a sequence homology search. these would allow detection of ca2+-binding proteins in the serum of various diseases and disorders, potentially leading to identification of novel biomarkers for disease diagnostics. we would like to use blood samples to carry out the procedure described above for identification of ca2+ binding proteins appearing or their level is increased in disease or under pathogenic conditions. since ca2+ binding proteins play an important role in bone metabolism, we chose to test their occurrence in the serum of patients with osteoporosis and other metabolic bone diseases.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of a metabolic bone disorder exclusion criteria: * none
clinical neuropharmacology of pain in spinal cord injury- dextromethorphan dose response clinical trial

Conditions: Central Neuropathic Pain; Allodynia; Spinal Cord Injury

Summary: this randomized, placebo-controlled, double-blind 4x4 crossover clinical trial was part of a larger nih-funded study to evaluate the analgesic efficacy of three doses of chronic oral (po) dextromethorphan compared to placebo in central neuropathic pain following spinal cord injury. subjects' maximally tolerated doses (mtd) were first determined to establish individual dose-analgesic response relationships in a run-in period; following a washout period, subjects were then randomized to receive an order of four doses of dextromethorphan (including placebo) in a 4x4 latin square cross-over design.


Eligibility criteria:
inclusion criteria: 1. healthy male or female adults, age 18 to 70 with central neuropathic pain for a minimum of 3 months following sci as confirmed by neurologic evaluation, with an average pain intensity score of at least moderate over at least 50% of the day for the 7 days prior to the screening visit and over the 7 days prior to starting study medication. 2. subjects used no medication or a stabilized medication regimen for chronic and well-controlled medical conditions 3. serum laboratory examination obtained at study entry: * liver function tests (albumin within 20% of normal, sgot/sgpt within 50% of normal). * for women of childbearing age: negative serum beta hcg. 4. postmenopausal women, or be physically incapable of childbearing, or be practicing an acceptable method of birth control. 5. normal cognitive function. 6. normal communicative ability (english). 7. ability to demonstrate competence in recording five times daily in pain diary for 1 week (with 100% compliance), and in completing required questionnaires. 8. signed informed consent. exclusion criteria: 1. pregnancy or breast-feeding. 2. renal or hepatic dysfunction. 3. significant cardiac disease (e.g. mi within 1 year). 4. signs or symptoms of central neurological disorder, excluding sci. 5. severe psychological disorder requiring treatment. 6. concurrent use of monoamine oxidase inhibitors within 2 weeks prior to study entry. 7. use of known cyp2d6 (but not cyp3a4) inhibitors or inducers. 8. history of hypersensitivity or intolerance to dextromethorphan or lidocaine. 9. chronic substance abuse, including alcohol. 10. participation in a study of an investigational drug or device within 30 days prior to screening for this study. 11. poor metabolizer of p450 2d6 substrates.

Keywords: chronic pain central neuropathic pain spinal cord injury dextromethorphan lidocaine combination therapy analgesia
vaginal administration of ala vs progesterone for the subchorionic hematoma treatment

Conditions: Subchorionic Hematoma in the First Trimester Pregnancy; Miscarriage

Summary: the aim of this study was to compare the therapeutic efficacy of lipoic acid versus progesterone by vaginal administration on subchorionic hematoma resorption in women at the first trimester of pregnancy with threatened miscarriage.


Eligibility criteria:
inclusion criteria: * age: 24-37 * gestational week: 7- 12 * evidence of threatened miscarriage (pelvic pain with or without vaginal bleeding) * ultrasound evidence of subchorionic hematoma exclusion criteria: * lack of fetus * absence of fetal heart tone * uterine anomaly or fetal anomaly * presence of multiple pregnancy * gestation pathology * therapies with anti-coagulants or anti-hypertensive drugs
liver disease in adults with alpha-1 at deficiency

Conditions: Alpha-1 AT Deficiency

Summary: this cohort study will evaluate the prevalence of the infra clinical liver injuries among a group of adult patients presenting with alpha-1 at deficiency followed up in a large university hospital in lyon, france.


Eligibility criteria:
inclusion criteria: * patients over 18 years old * presenting an alpha-1 at deficiency (alpha-1 at level \<0.8g/l at the time of diagnosis) exclusion criteria: * patients presenting a liver disease not related to the alpha-1 at deficiency

Keywords: alpha-1 at deficiency liver injury transient elastography fibrotest
pharmacokinetic model of fibrinogen plasma levels after fibrinogen administration

Conditions: Fibrinogen; Deficiency, Acquired; PHARMACOKINETICS

Summary: characterize the fibrinogen pk in patients with acquired -chronic (cirrhotic patients) or acute- hypofibrinogenemia (severe trauma or critical haermorrhage), showing endogenous production.

fibrinogen, a plasma-soluble protein synthesized by the liver, is the key substrate for the plasmatic blood coagulation, reaching a critically low plasma concentration earlier than other coagulation factors in case of bleeding. fibrinogen pharmacokinetics (pk) after single doses of fibrinogen concentrate (fc), using modeling approaches, has only been evaluated in congenital afibrinogenaemic patients. the aims of this study are to extend the modeling process to characterize the fibrinogen pk in patients with acquired -chronic (cirrhotic patients) or acute- hypofibrinogenemia (severe trauma or critical haermorrhage), showing endogenous production. influencing factors of differences on the fibrinogen pk between sub-populations will be identified.

Eligibility criteria:
inclusion criteria: afibrinogenemic, traumatic and cirrhotic after fibrinogen administration - exclusion criteria: na -
study evaluating the potential of dvs sr to inhibit the cyp2d6 pathway

Conditions: Depressive Disorder, Major; Diabetic Neuropathies; Fibromyalgia; Vasomotor Symptoms

Summary: to evaluate the effects of multiple oral doses of desvenlafaxine sustained release (dvs sr) and paroxetine on the biotransformation of codeine to morphine in healthy subjects. to assess the safety and tolerability of dvs sr and paroxetine when coadministered with codeine to healthy subjects.

this is a randomized, open-label, inpatient/outpatient, 3-period crossover study in healthy subjects.the study will consist of 3 treatment periods. in treatment period 1, subjects will be randomly assigned on study day 1. a single 60-mg dose of codeine will be administered to all subjects. in periods 2 and 3, subjects will receive either dvs sr 100 mg/day or paroxetine 20 mg/day until the steady state is reached. at steady state, subjects will receive codeine 60 mg concomitantly with either dvs sr 100 mg or paroxetine 20 mg, depending on the treatment sequence to which they are assigned. dvs sr 100 mg or paroxetine 20 mg administration will continue for an additional 2 days. in treatment period 3, subjects will receive the alternative treatment sequence.

Eligibility criteria:
inclusion criteria: * healthy men and nonlactating and nonpregnant women of nonchildbearing potential aged from 18 to 45 years. * body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg. * nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. exclusion criteria: * history of bronchial asthma, of seizure disorder (other than a single childhood febrile seizure)and of any clinically important drug allergy and any known allergy to desvenlafaxine, venlafaxine, paroxetine, codeine, or any of the non-active excipients in the dosage forms. * use of any cyp2d6 inhibitors or inducers within 30 days before test article administration. * demonstration of a positive orthostatic test at screening.
the treatment and intra-operative imaging of scaphoid fracture reduction and fixation

Conditions: Scaphoid Fractures

Summary: scaphoid fractures are the most common carpal bone fractures, and second most common wrist fractures (second to distal radius fractures). lack of proper immobilization or displacement of these fractures commonly results in fracture nonunion or malunion followed by the development of wrist post-traumatic osteoarthritis. in addition, proper reduction and fixation of these fractures are challenging to the most experienced hand surgeons. the investigators are going to follow-up the patients population suffering from scaphoid fractures(nonunion included) for one year. the investigators will evaluate this follow up results in two ways: 1. intra-operative imaging of scaphoid fracture fixation - feasibility evaluation. 2. treatment of scaphoid fracture non-union.


Eligibility criteria:
inclusion criteria: 1. ages of 18 and 60 during the study period; 2. scaphoid fractures to be operatively reduced and fixated, including fracture non-unions; 3. signed informed consent. exclusion criteria: 1. non-displaced fractures of the scaphoid. 2. soldiers in active military service. 3. pregnant women

Keywords: fracture in the scaphoid fractures